retatrutide patent status tirzepatide off patent The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational tirzepatide patent expiry 2036 GLP-1 – Retatrutide CAS 2381089-83-2 | Manufacturer
Pay in 4 interest-free payments of $7.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4























